

Table 15.7
Immunosuppression Use for Maintenance by Regimen
Two Years Following Transplantation, 1999 to 2007
Recipients with Kidney Transplants

	Transplant Year								
	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	12,765	13,620	14,276	14,779	15,137	16,006	16,483	17,095	16,634
Functioning Graft at 2 Years PostTx	10,225	11,064	11,837	12,311	12,633	13,388	13,767	14,550	14,340
With Maintenance Use Recorded at 2 Years PostTx	9,705	10,831	11,529	11,993	12,344	13,041	11,104	10,795	10,371
CyA	0.7%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.2%	0.1%
Tac	0.8%	0.8%	1.5%	1.8%	1.9%	2.3%	3.1%	3.1%	2.6%
--- + MMF/MPA	0.1%	0.1%	0.1%	0.1%	0.3%	0.3%	0.3%	0.2%	0.2%
CyA + MMF/MPA	1.1%	1.4%	1.5%	1.7%	2.3%	2.3%	2.1%	1.6%	1.5%
Tac + MMF/MPA	2.2%	2.9%	4.4%	6.5%	9.9%	15.5%	22.1%	26.0%	27.5%
--- + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet	0.2%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.0%	0.0%
Tac + OtherAntimet	0.2%	0.2%	0.2%	0.3%	0.2%	0.3%	0.4%	0.6%	0.7%
--- + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + Siro/Evero	0.0%	0.2%	0.3%	0.2%	0.1%	0.2%	0.2%	0.2%	0.1%
CyA + Siro/Evero	0.2%	0.3%	0.4%	0.8%	0.8%	0.8%	1.0%	0.8%	0.8%
Tac + Siro/Evero	0.1%	0.9%	2.1%	2.4%	2.7%	2.1%	1.6%	1.0%	0.7%
--- + MMF/MPA + Siro/Evero	0.0%	0.2%	0.5%	0.7%	1.4%	1.9%	2.4%	2.5%	2.0%
CyA + MMF/MPA + Siro/Evero	0.0%	0.1%	0.1%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%
Tac + MMF/MPA + Siro/Evero	0.1%	0.2%	0.3%	0.5%	0.8%	0.7%	0.8%	0.6%	0.7%
--- + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + Steroids	0.7%	0.3%	0.5%	0.4%	0.5%	0.2%	0.2%	0.2%	0.2%
CyA + Steroids	6.9%	4.1%	2.4%	1.5%	1.4%	0.9%	0.7%	0.5%	0.6%
Tac + Steroids	7.2%	7.4%	6.5%	6.1%	5.1%	4.5%	4.4%	4.7%	5.2%
--- + MMF/MPA + Steroids	2.0%	1.4%	1.3%	1.3%	1.1%	1.2%	1.1%	0.9%	0.7%
CyA + MMF/MPA + Steroids	36.3%	31.0%	22.8%	18.5%	14.0%	12.1%	7.4%	5.1%	4.3%
Tac + MMF/MPA + Steroids	27.3%	29.7%	35.0%	38.6%	41.3%	40.0%	40.4%	41.0%	43.2%
--- + OtherAntimet + Steroids	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
CyA + OtherAntimet + Steroids	4.6%	2.9%	1.5%	0.7%	0.5%	0.3%	0.2%	0.1%	0.2%
Tac + OtherAntimet + Steroids	2.1%	2.0%	2.0%	1.6%	1.4%	1.3%	1.3%	1.6%	1.6%
--- + Siro/Evero + Steroids	0.5%	0.7%	1.0%	0.7%	0.9%	0.9%	0.8%	0.5%	0.5%
CyA + Siro/Evero + Steroids	2.3%	3.7%	2.9%	2.5%	1.9%	1.4%	1.1%	1.0%	1.1%
Tac + Siro/Evero + Steroids	1.3%	4.8%	6.5%	5.6%	4.4%	3.2%	2.3%	1.8%	0.9%
Other Regimen	3.0%	4.2%	5.8%	6.9%	6.7%	7.1%	5.7%	5.3%	4.2%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.